High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin - PubMed (original) (raw)

High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin

Fiona Fouhy et al. Antimicrob Agents Chemother. 2012 Nov.

Abstract

The infant gut microbiota undergoes dramatic changes during the first 2 years of life. The acquisition and development of this population can be influenced by numerous factors, and antibiotic treatment has been suggested as one of the most significant. Despite this, however, there have been relatively few studies which have investigated the short-term recovery of the infant gut microbiota following antibiotic treatment. The aim of this study was to use high-throughput sequencing (employing both 16S rRNA and rpoB-specific primers) and quantitative PCR to compare the gut microbiota of nine infants who underwent parenteral antibiotic treatment with ampicillin and gentamicin (within 48 h of birth), 4 and 8 weeks after the conclusion of treatment, relative to that of nine matched healthy controls. The investigation revealed that the gut microbiota of the antibiotic-treated infants had significantly higher proportions of Proteobacteria (P = 0.0049) and significantly lower proportions of Actinobacteria (P = 0.00001) (and the associated genus Bifidobacterium [P = 0.0132]) as well as the genus Lactobacillus (P = 0.0182) than the untreated controls 4 weeks after the cessation of treatment. By week 8, the Proteobacteria levels remained significantly higher in the treated infants (P = 0.0049), but the Actinobacteria, Bifidobacterium, and Lactobacillus levels had recovered and were similar to those in the control samples. Despite this recovery of total Bifidobacterium numbers, rpoB-targeted pyrosequencing revealed that the number of different Bifidobacterium species present in the antibiotic-treated infants was reduced. It is thus apparent that the combined use of ampicillin and gentamicin in early life can have significant effects on the evolution of the infant gut microbiota, the long-term health implications of which remain unknown.

PubMed Disclaimer

Figures

Fig 1

Fig 1

Microbial distributions at the phylum level in the samples from treated and control infants at week 4 and week 8. Statistically significant differences between treated infants and controls at week 4 are indicated by asterisks (P < 0.05). Statistically significant differences between treated infants and controls at week 8 are indicated by asterisks. A statistically significant difference between treated infants at week 4 and week 8 (i.e., the recovery of the treated infants) is indicated by a diamond. Percentages are based on proportions of assignable tags.

Fig 2

Fig 2

Microbial distributions at the family level in the samples from treated and control infants at week 4 and week 8. Statistically significant differences between treated infants and controls at week 4 are indicated by asterisks (P < 0.05). Statistically significant differences between treated infants and controls at week 8 are indicated by asterisks. A statistically significant difference between treated infants at week 4 and week 8 (i.e., the recovery of the treated infants) is indicated by a diamond. Percentages are based on proportions of assignable reads.

Fig 3

Fig 3

Microbial distributions at the genus level in the samples from treated and control infants at week 4 and week 8. Statistically significant differences between treated infants and controls at week 4 are indicated by asterisks (P < 0.05). Statistically significant differences between treated infants and controls at week 8 are indicated by asterisks. A statistically significant difference between treated infants at week 4 and at week 8 (i.e., the recovery of the treated infants) is indicated by a diamond. Percentages are based on proportions of assignable reads.

Fig 4

Fig 4

Individual distributions of bifidobacteria in the treated (B1 to H1 and B2 to H2) and control (J1 to R1 and J2 to R2) samples as detected by using rpoB amplicons for 454 pyrosequencing. Values show the percentage of the different bifidobacterial species present in the individual samples. Samples from treated infants show far less variability both between samples and also between week 4 and week 8 than the controls. The x axis indicates individual infants; the y axis shows the percentage of total bifidobacteria assigned to each species.

Similar articles

Cited by

References

    1. Abrahamsson TR, et al. 2011. Low diversity of the gut microbiota in infants with atopic eczema. J. Allergy Clin. Immunol. 129:434–440 - PubMed
    1. Acred P, Brown D, Turner D, Wilson M. 1962. Pharmacology and chemotherapy of ampicillin—a new broad-spectrum penicillin. Br. J. Pharmacol. Chemother. 18:356–369 - PMC - PubMed
    1. Adlerberth I, Wold AE. 2009. Establishment of the gut microbiota in Western infants. Acta Pædiatr. 98:229–238 - PubMed
    1. Ajslev T, Andersen C, Gamborg M, Sørensen T, Jess T. 2011. Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics. Int. J. Obesity 35:522–529 - PubMed
    1. Altschul SF, et al. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25:3389–3402 - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources